Ensartinib hydrochloride capsules officially launched in China
On November 19, 2020, the National Food and Drug Administration (FDA) of China announced that the ALK inhibitor Ensartinib Hydrochloride Capsules (Bemena®) independently developed by Betta Pharmaceuticals was officially approved for marketing in China. Second-line treatment of ALK-positive non-small cell lung cancer patients.
Ensartinib Hydrochloride (Bemena®) is a new-generation, potent and highly selective ALK inhibitor jointly developed by Betta Pharmaceuticals and its subsidiary Xcovery Holding, Inc. with completely independent intellectual property rights, another major product in the field of lung cancer after EGFR-TKI. It is China’s first domestically produced Class 1 new drug for the treatment of ALK-mutated advanced non-small cell lung cancer, and is expected to become the first Chinese company to dominate the world Innovative targeted lung cancer drugs on the market.